A vs AKAM Stock Comparison

Scores Breakdown

Metric	A	AKAM
📈 Growth	26/30	22/30
💰 Profitability	17/20	17/20
🏦 Financial Health	15/20	17/20
💵 Valuation	16/20	16/20
⚠️ Risk (lower is better)	5/10	4/10
Overall Score	79/100	78/100

Side-by-Side Summaries

A Analysis	AKAM Analysis
📈 Growth & Financial Trajectory Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility. 💰 Margins & Cash Flow Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity. 🛡️ Balance Sheet & Liquidity Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure. ⚠️ Key Drivers & Risks Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption. Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.	📈 Growth & Financial Trajectory Over the 8 quarters, AKAM's revenues rose from about $1.00B to about $1.10B, a modest expansion of ~9-10%, with a steady uptrend across quarters. Net income moved from roughly $58M in 2024-Q3 to a peak of about $140M in 2025-Q3, before printing around $79M in 2026-Q2, reflecting quarterly volatility but positive trajectory. 💰 Margins & Cash Flow Gross margin stayed robust in the mid-to-high 50s% (Q2 2026 ~55.8%; Q4 2025 ~58.6%; Q3 2025 ~59.2%). Operating income remained positive in every quarter shown. Operating cash flow (continuing) was solid, e.g., around $326M in 2026-Q2. Net cash flow turned positive in 2026-Q2 at roughly $0.85B, with investing cash outflows offset by financing inflows in several quarters, indicating healthy cash generation despite capex. 🛡️ Balance Sheet & Liquidity Assets near $15.1B in 2026-Q2, liabilities around $10.3B, and equity about $4.75B. Current assets vs current liabilities yield a comfortable liquidity cushion (approx. 1.6x). Leverage remains moderate with substantial noncurrent assets and conservative equity backing. ⚠️ Key Drivers & Risks Drivers: AI/Data Center edge/CDN demand; sustained enterprise traffic growth. Risks: Revenue cyclicality and competition; valuation sensitive to margin shifts and growth pace.

A Analysis

AKAM Analysis

📈 Growth & Financial Trajectory

Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility.

💰 Margins & Cash Flow

Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity.

🛡️ Balance Sheet & Liquidity

Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure.

⚠️ Key Drivers & Risks

Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption.
Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.

📈 Growth & Financial Trajectory

Over the 8 quarters, AKAM's revenues rose from about $1.00B to about $1.10B, a modest expansion of ~9-10%, with a steady uptrend across quarters. Net income moved from roughly $58M in 2024-Q3 to a peak of about $140M in 2025-Q3, before printing around $79M in 2026-Q2, reflecting quarterly volatility but positive trajectory.

💰 Margins & Cash Flow

Gross margin stayed robust in the mid-to-high 50s% (Q2 2026 ~55.8%; Q4 2025 ~58.6%; Q3 2025 ~59.2%). Operating income remained positive in every quarter shown. Operating cash flow (continuing) was solid, e.g., around $326M in 2026-Q2. Net cash flow turned positive in 2026-Q2 at roughly $0.85B, with investing cash outflows offset by financing inflows in several quarters, indicating healthy cash generation despite capex.

🛡️ Balance Sheet & Liquidity

Assets near $15.1B in 2026-Q2, liabilities around $10.3B, and equity about $4.75B. Current assets vs current liabilities yield a comfortable liquidity cushion (approx. 1.6x). Leverage remains moderate with substantial noncurrent assets and conservative equity backing.

⚠️ Key Drivers & Risks

Drivers: AI/Data Center edge/CDN demand; sustained enterprise traffic growth.
Risks: Revenue cyclicality and competition; valuation sensitive to margin shifts and growth pace.

Similar Companies

AMAT Score: 79 AME Score: 78 ANET Score: 85 GOOGL Score: 80 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"